Mon, May 16, 2022
A big hit of around 40-50 per cent on the profitability of diagnostic companies such as Metropolis Healthcare and Dr Lal Path Labs among others is likely expected, Zee Business Senior Research Analyst Kushal Gupta said in his exclusive research report on Monday.
More >
Wed, Apr 20, 2022
According to brokerage firm IIFL Securities, “The Indian diagnostics industry offers consistent and long-term growth potential of around 11-12 per cent, and national diagnostic chains would continue to outperform industry growth.”
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
!["Achhe Din" for common man as Tata 1mg's launches B2C segment; Metropolis, Dr Lal Path profits to get hit says Zee Business exclusive research](https://cdn.zeebiz.com/sites/default/files/styles/zeebiz_160x90/public/2022/05/16/182685-anil-singhvi-tata-1mg.JPG?itok=AVz4MrbB&c=96e35c1a32f738debe61a8c01c638b91 ""Achhe Din" for common man as Tata 1mg's launches B2C segment; Metropolis, Dr Lal Path profits to get hit says Zee Business exclusive research")
